This is a very interesting article that should kindle in-depth conversations about the descriptions we use to summarize clinical trials in myeloma. The overarching message of this paper is that it is not uncommon to minimize toxicities, even when some clearly have a significant impact on patients. Some things have always bothered me, such as how language can minimize toxicity or seem outright erroneous, and this paper is important documentation. I have some points of agreement with the interpretation but also some of disagreement. I realize the authors have much more to say as the paper is a medical publication focused on the data presented, but this paper stirred many thoughts. I will consider it a conversation starter. Let me explain.